Plus   Neg

Teva Sees 2018 Below View; Stock Plunges

Teva Pharmaceutical Industries Ltd. (TEVA) said that it expects non-GAAP earning per share to be in the range of $2.25-$2.50, and revenues of $18.3 billion -$18.8 billion for fiscal year 2018. Analysts polled by Thomson Reuters expect the company to report earnings of $2.94 per share and revenues of $19.26 billion for 2018. Analysts' estimates typically exclude special items.

In the Thursday pre-market, TEVA is trading at $18.10 down $2.76 or 13.23%.

As part of restructuring plan, in December 2017, the company announced an immediate suspension of dividends on ordinary shares and ADSs and that dividends on mandatory convertible preferred shares will be evaluated on a quarterly basis per current practice.

Teva has suspended dividends on its mandatory convertible preferred shares in the fourth quarter of 2017, due to its negative net retained earnings.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Amazon.com Inc.'s (AMZN) Chief Executive Jeff Bezos has told the company's employees said that the tech giant is not too big to fail, according to media reports. Shares of Nordstrom Inc. (JWN) slipped 10 percent in extended hours on Thursday after the department store chain's full-year revenue outlook fell short of Street estimates. Seattle-based Nordstrom's third-quarter profit dropped to $67 million or $0.39 per share from $114 million or $0.67 per share... Shares of Nvidia Corp. (NVDA) plunged 16% in extended session on Thursday after chip designer's third-quarter revenues and fourth quarter outlook fell short of Wall Street estimates. Santa Clara, California-based Nvidia's third-quarter profit surged to $1.23 billion or $1.97 per share from $838 million...
Follow RTT